We are committed to delivering better health to patients with cancer.
Our nanoparticle delivery system provides the opportunity to improve the safety, efficacy and dosing of existing, novel, and synergistic combinations of cancer drugs. We achieve this by targeting the activity of the drug(s) within the tumor environment and keeping healthy tissues protected. We are dedicated to serving patients with rare forms of cancer and creating shareholders value by advancing our development programs efficiently.
Our top priority is to develop our lead product candidates as improved treatments for Metastatic Soft Tissue Sarcoma, ES-Small Cell Lung Cancer and Multiple Myeloma, with plans to expand rapidly into other cancers.